Please login to the form below

Not currently logged in

IFPMA appoints director general

Thomas Cueni brings expertise from Interpharma and EFPIA

The International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) has selected Thomas Cueni as its new director general.

Cueni takes on responsibility for representing the interests of the research-based pharma industry at a global level, working with organisations and governments to promote the value of pharmaceutical innovation and improve access to treatments.

He brings considerable experience as secretary general of Interpharma, the Basel-based association representing Swiss pharma firms, during which time he had been closely associated with IFPMA as a member of its council.

Cueni also brings industry expertise from the European Federation of Pharmaceutical Industries and Associations (EFPIA), where he served in a policy-shaping and advocacy capacity.

Ian Read, IFPMA's president and chief executive and chairman of Pfizer, said: “Thomas has extensive experience in the research-based biopharmaceutical industry and a deep understanding of what is needed to support the continued discovery and development of important life-saving and life-enhancing medicines and vaccines.

“I look forward to working closely with Thomas in advocating for sustainable health policies that foster innovation and ensure patient access to these important advances.”

8th February 2017

From: Healthcare



Featured jobs

Subscribe to our email news alerts


Add my company

Wisepress is a medical bookseller promoting and selling books worldwide, both online and via the 200 European medical conferences that...

Latest intelligence

How to get rep buy-in for multi-channel
How do you manage a team who may be resistant to change?...
Blog: Digital therapeutics: within our reach?
Digital therapeutics is a hot topic right now. By using digital technology to manage, treat or even prevent chronic conditions, digital therapeutics is promising to revolutionise healthcare. But is this...
figure 1
The valuable brand
Creating value beyond the pill is both possible and increasingly necessary...